Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
NK1 receptor antagonist wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Neuropharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Disorders of Hemostasis Hereditary Disorders of Hemostasis Von Willebrand’s Disease The most common inherited bleeding disorder in humans (1% to 2 % of the Population) Caused by a quantitative or qualitative defect of the vWF vWF is a protein synthesized by endothelial cells, megakaryocytes, and platelets that is essential for platelet plug formation. o vWF binds platelets to subendothelial surface of injured blood vessels. After binding to the subendothelium, vWF binds the GPIb receptor on the surface of platelets. o vWF also participates in platelet aggregation by binding to the GPIIb/IIIa receptors on the surface of several platelets. o It is also important in coagulation as a carrier protein and stabilizer for factor VIII vWF has several potential binding sites: o On collagen for adherence to the subendothelium o On the platelet GPIb receptor for platelet adhesion to collagen o On the platelet GPII3/IIIa receptor for platelet aggregation o On factor VIII for its carrier function Classification of vWD o Type I (the most common form) - a quantitative deficiency of vWF. o Type 2 – several subtypes with different qualitative defects vWF o Type 3 (least common, most severe) – complete absence of vWF Acquired forms of vWD o o o o o Lymphoproliferative diseases Autoimmune disease Hypothyroidism Valvular heart defects Medications such as valproic acid Clinical manifestations of vWD o o o o o o o Mucocutaneous bleeding Easy bruising Epistaxis Gingival bleeding GI bleeding Menorrhagia History of significant bleeding with previous surgeries Laboratory diagnosis of vWD o Platelet count, PT and PTT may well be normal o Hematology consult and specialized testing may be in order o Ristocetin cofactor activity - most sensitive and specific test for vWD Two established modes of treatment for vWD - desmopressin and factor replacement therapy o Desmopressin (DDAVP) – a synthetic analog of the antidiuretic hormone vasopressin Triggers the release of both vWF and factor VIII 0.3 g/kg for pre-op prophylaxis will increase factor VIII and vWF two- to five-fold in most patients. Side effects – flushing, tachycardia, headache from the vasomotor effects of DDAVP, and hyponatremia and seizures from the antidiuretic effects. (Monitor serum Na) o Factor VIII and vWF concentrate replacement therapy For patients who do not respond to DDAVP Haemate-P, cryoprecipitate or FFP o Antifibrinolytic amino acid therapy Sometimes used in combination with DDAVP to manage vWD patients during the perioperative period. Anti-fibrinolytic drugs interfere with the lysis of newly formed clots -Aminocaproic acid 50 to 60 mg/kg q 4 to 6 hours Tranexamic acid 20 to 25 mg/kg q 8 to 12 hours o Anti-platelet drugs should be avoided in patients with vWD. Hemophilias Inherited bleeding disorders caused by deficiencies of certain coagulation factors o Hemophilia A – deficiency of factor VIII o Hemophilia B – deficiency of factor IX o Hemophilia C – deficiency of factor XI Both are X-linked recessives and occur almost exclusively in males Clinical presentation o Unexplained bruising or bleeding in young males o Arthropathies due to recurrent hemarthrosis and chronic synovitis o Hematuria Testing o APTT prolonged in both Hemophilia A and B o PT, platelet count, vWF levels, and fibrinogen levels are normal o Factor VIII and IX levels are low Treatment and Perioperative Management o Factor replacement therapy – either plasma-derived concentrates that have been treated by viral attenuation, or, more commonly now, recombinant factor VIII or factor IX o Obtain hematology consult for perioperative management advice. o DDAVP will increase plasma factor VIII and vWF concentrations and may be effective in mild hemophilia A. o Antifibrinolytics may be useful prior to dental procedures, but are contraindicated in bleeding episodes involving joints or the urinary tract because clots that do form may not be lysed for a long period of time. Protein C and Protein S Deficiency Hereditary deficiencies of protein C and protein S Associated with thromboembolic events originating on the venous side of the circulation (eg, DVT, PE, and stroke) as a consequence of paradoxical embolization. Patients with a history of thromboembolic events and a deficiency of protein S or protein C should remain on anticoagulants indefinitely. Inherited platelet disorders Involve quantitative or qualitative impairment of platelet function Idiopathic thrombocytopenic purpura (ITP) o Commonly found in children o Adult patients present with isolated thrombocytopenia and a normal peripheral blood smear o Secondary immune thrombocytopenia can occur following exposure to drugs, herbs, foods, or other substances o Can also follow SLE, antiphospholipid syndrome, B-cell malignancies, and HIV Acquired Disorders of Hemostasis Acquired Disorders of Platelets Thrombocytopenia Platelets are produced by megakaryocytes in the bone marrow in response to thrombopoetin, which is synthesized in the liver. Causes of thrombocytopenia: o Inadequate production by the bone marrow Secondary to bone marrow suppression of any cause o Increased peripheral consumption or destruction (non-immune related) Extensive activation of coagulation mechanisms after trauma, burns, and crush injuries, or contact with large vascular grafts Extensive vasculitis as occurs with toxemia of pregnancy DIC o Increased peripheral destruction (immune related) Drug related, autoimmune reactions, and alloimmunization o Dilution of circulating platelets o Sequestration Uremia Platelet dysfunction is common in uremia Accumulated substances interfere with ability of the platelet to expose the PF3 phospholipid surfaces. Dialysis improves the hemostatic defect DDAVP improves platelet adhesiveness Erythropoiten will gradually improve platelet function Platelet concentrates may be indicated if life-threatening bleeding occurs in a uremic patient. Anti-Platelet Drugs Numerous medications are administered expressly for the purpose of platelet inhibition in order to reduce the risk of MI, stroke and other thromboembolic events. They induce platelet dysfunction by several mechanisms: o o o o Inhibition of cyclooxygenase Inhibition of phosphodiesterase ADP receptor antagonism Blockade of glycoprotein IIb/IIIa receptor Cyclooxygenase (COX) inhibitors: o Aspirin – non-selective COX inhibitor Irreversibly inhibits platelet cyclooxygenase, which blocks the synthesis of thromboxane A2, a potent platelet aggregator and vasoconstrictor. o NSAIDs inhibit cyclooxygenase in a similar manner, but their effect is reversible in 24 hr with clearance of the drug. o COX-2 inhibitors selectively inhibit the COX-2 isoform, which mediates pain and inflammation, and spare the COX-1 isoform, responsible for gastric damage, decreased renal blood flow, and platelet thromboxane A2 synthesis. Phosphodiesterase inhibitors o Cyclic AMP is an inhibitor of platelet aggregation and cAMP levels are increased by inhibition of phosphodiesterase. o Dipyridamole and cilostazol act by this mechanism ADP receptor antagonists o Clopidogrel (Plavix) and ticlopidine (Ticlid) block the ADP receptor on the platelet surface, which suppresses activation of the GPIIb/IIIa receptor. o They non-competitively and irreversibly inhibit ADP-induced platelet aggregation. o Platelet function normalizes 7 days after discontinuation of clopidogrel and 14 days after for ticlopidine. GP IIb/IIIa receptor antagonists o Abcixamab (ReoPro), a monoclonal antibody, Tirofiban (Aggrastat), and Eptifibatide (Integrilin). o Block binding of fibrinogen and vWF factor to platelet GPIIb/IIIa receptors, inhibiting platelet aggregation. o Effects are reversible, half-lives are relatively short o All are associated with thrombocytopenia Herbal Medications and Vitamins Several herbal medications, including ginkgo biloba, ginseng, garlic, and ginger, may inhibit platelet function. Vitamin E is also a platelet inhibitor Other Conditions Myeloproliferative and myelodysplastic syndromes can induce intrinsic defects in platelets. Platelets may be abnormal in both morphology and function. Acquired Disorders of Clotting Factors Liver Disease Chronic liver disease is associated with abnormalities of all three phases of hemostasis: primary hemostasis, coagulation and fibrinolysis. Impaired primary hemostasis is the result of both thrombocytopenia (decreased production) and impaired platelet function (insufficient clearance of FDPs, which coat the surface of platelets and impair aggregation). Coagulation is impaired because factor production decreases and consumption increases. Fibrinolysis is increased as a result of decreased clearance of t-PA from the circulation by the impaired liver, and decreased hepatic synthesis of alpha 2antiplasmin, a natural inhibitor of plasmin. DIC DIC is characterized by excessive deposition of fibrin throughout the vascular tree, with simultaneous depression of normal coagulation inhibitory mechanisms and impaired fibrin degradation. DIC is triggered by the appearance of procoagulant material (eg, tissue factor) in the circulation in amounts sufficient to overwhelm the mechanisms that normally restrain and localize clot formation. o May result from extensive tissue injury – burns or trauma o May also result from the release of tissue factor into the circulation Sepsis is the most common cause. Amniotic fluid embolus, fetal death in utero, preeclampsia Severe head injury or stroke Any cause of systemic inflammatory response Hemolytic transfusion reactions The accelerated process of clot formation causes both tissue ischemia and critical depletion of platelets and clotting factors. Simultaneously, the fibrinolytic system is activated and plasmin is generated to lyse the extensive fibrin clots. Fibrin degradation products appear in the circulation. o FDPs stimulate the release of plasminogen activator inhibitor from endothelium, and thrombolysis becomes impaired. o FDPs also inhibit platelet aggregation and prevent normal crosslinking of fibrin monomers. Depleted of platelets and clotting factors, and inhibited by FDPs, the coagulation system fails and the patient bleeds. Simultaneously, microvascular occlusion by fibrin causes tissue ischemia, contributing to multi-organ failure. Laboratory diagnosis - increased PT and PTT, thrombocytopenia, decreased fibrinogen level, and the presence of FDPs and D-dimers Treatment should focus on management of the underlying condition. o Correct hypovolemia, acidosis, and hypoxemia. o Platelet infusion for thrombocytopenia o FFP to replace deficient clotting factors o Cryoprecipitate to raise fibrinogen o Heparin may be useful if thrombosis is a significant problem Vitamin K Deficiency Vitamin K is required for the hepatic synthesis of factors II, VII, IX and X, as well as proteins C and S. Each of the vitamin K dependent factors undergoes the enzymatic addition of a carboxyl group. This step requires the presence of vitamin K. The carboxyl group enables these factors to bind to phospholipid surfaces. Without vitamin K, factors II, VII, IX and X are produced in normal amounts but are nonfunctional. Vitamin K is a fat-soluble vitamin and therefore requires bile salts for absorption from the jejunum. Patients with biliary obstruction, pancreatic insufficiency, malabsorption syndromes, GI obstruction, or rapid GI transit can develop vitamin K deficiency as a result of inadequate absorption. Vitamin K deficiency will cause prolongation of the PT. Vitamin K can be administered PO, IM, or IV Therapy can take several days, but improvement of the coagulation abnormality should be apparent within 6 to 8 hours after IM or IV administration. Warfarin Therapy Warfarin produces its anticoagulant effect by competing with vitamin K for carboxylation binding sites in the liver. Warfarin leads to the depletion of factors II, VII, IX, and X. At theraputic doses, only the PT and INR will be prolonged. If time allows, stop the medication 4 to 5 days ahead of surgery to normalize the PT. More rapid reversal can be accomplished with oral or parenteral vitamin K. Immediate reversal is achieved with FFP, prothrombin complex concentrate, or recombinant factor VIIa. However, vitamin K should still be administered because of the short half-life of those substances. Heparin Therapy Heparin inhibits coagulation principally by binding to antithrombin III, which greatly increases the inhibitory effect of ATIII on thrombin and other coagulation factors. Advantages of unfractionated heparin over LMWH or fondaparinux: o Immediate onset o Short half-life of 30 to 60 min o Reversibility with protamine Needs to be closely monitored because of unpredictable pharmacokinetics Generally, the use of low-dose or mini-dose unfractionated heparin for thromboprophylaxis poses a low risk for hemorrhage during surgery. On the other hand, patients receiving therapeutic doses of standard heparin are at high risk of bleeding during surgery. Heparin should be stopped at least 6 hours before surgery, and restarted about 12 hours after surgery. Protamine sulfate can be used for immediate reversal of heparin anticoagulation. Complications of heparin therapy: o Heparin-induced thrombocytopenia/thrombosis (HITT) HITT type 1 is self-limiting and requires no treatment. HITT Type 2 - as many as 5% of patients who receive heparin therapy for 5 days will develop thrombocytopenia as a result of antibodies (usually IgG) directed against platelet factor 4heparin complexes on the platelet surface. The onset on HITT is signaled by a rapid drop in the platelet count 5 to 10 days after initiation of heparin therapy. Mortality is 20% to 30%. Though HITT is most often identified by thrombocytopenia, not all patients become thrombocytopenic. In these patients, the onset of HITT may be heralded by thrombotic events including DVT, PE, limb ischemia, MI, or stroke. Treatment entails withdrawal of heparin after the institution of alternate anticoagulation. Resistance to heparin can occur in patients who are deficient in ATIII either on a hereditary or acquired basis (the latter is seen with prolonged heparin therapy or in the presence of a consumptive coagulopathy). Heparin function can be restored by the administration of ATIII concentrates or FFP. Low-molecular-weight-heparin (LMWH) Therapy LMWH is heparin cleaved into shorter fragments. Like heparin, LMWH acts by enhancing the effect of ATIII. LMWH has a delayed onset of 20 to 60 minutes, and a longer half-life than heparin. Peak plasma concentrations occur approximately 4 hr after the initial dose, and activity persists up to 24 hr. Used mostly for DVT prophylaxis and treatment Monitoring is not usually required or performed, but if it is deemed necessary, anti-Xa level is the appropriate test. Major disadvantage of LMWH is that it cannot be reversed LMWH causes less platelet inhibition than standard heparin, and is associated with a lower incidence of heparin-induced thrombocytopenia. Direct Thrombin Inhibitors Includes hirudin, argatroban, lepirudin, and bivalirudin o Used for anticoagulation during CPB when there are contraindications to heparin. o There is no reversal drug. Termination of effect is dependent on renal excretion. Inhibitors of Xa Includes fondaparinux and idraparinux o Increasingly popular for DVT prophylaxis because of once-a-day dosing and lack of need for monitoring. o Also, less risk of osteopenia and heparin-induced thrombocytopenia o Long half lives, no antidote, renal excretion o PT, PTT and ACT are not affected Thrombolytic agents Classified either as native tissue plasminogen activators (streptokinase, urokinase) or as exogenous tissue plasminogen activators (alteplase, tenecteplase) o Native tissue plasminogen activators are potent activators of plasminogen to form plasmin o Exogenous tissue plasminogen activators are more fibrin selective, with less effect on circulating plasminogen. o Both function as anticoagulants as well as thrombolytics because fibrinolysis generates increased amounts of circulating fibrin degradation products that inhibit platelet aggregation. o In general, surgery should be delayed for 10 days and until clotting tests are normal. Hypercoagulable Disorders Disorders that predispose patients to thrombosis o Can be inherited or acquired o Can be arterial or venous Acquired hypercoagulable disorders o Predispose patients to thrombosis by: Activating the coagulation system Inhibiting the fibrinolytic system Initiating platelet activation o o o o o o o o o o o o o Smoking Heparin-induced thrombocytopenia (HITT syndrome) Antiphospholipid syndrome Pregnancy Oral contraceptives Diabetes Mellitus Polycythemia Hyperfibrinogenemia Malignancy Sepsis Trauma Hyperthermia Immobility o Venous thrombosis is associated with venous stasis, hypercoagulable states, and vascular damage. o Venous blood flow is impaired in pregnancy, and with abdominal tumors, varicose veins, or conditions involving vascular damage such as vasculitis. o Hypercoagulable states are commonly associated with coronary artery disease, diabetes, malignancy, nephritic syndrome, prolonged bed rest, postoperative status, and sepsis. o Patients with artificial heart valves, atrial fibrillation, and certain types of valvular heart disease have an increased risk of arterial thrombosis. Congenital hypercoagulable disorders lead to intraoperative deep vein thrombosis and pulmonary embolism: o Involve congenital abnormalities of procoagulant and anticoagulant proteins o Factor V Leiden mutation o Protein C or S deficiencies o Anti-thrombin deficiency o Hyper-homocysteinemia o Increased Factor VIII or Factor IX levels o Dysfibrinogenemia o Increased plasminogen activator inhibitor levels o Decreased plasminogen activator o Hereditary conditions should be suspected in patients with a positive family history, recurrent thrombolic events, or thromboemboli at a young age without predisposing factors.